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1. Introduction
Mechanical alternans (MA) is a mysterious phenomenon. MA, a condition characterized by
beat-to-beat oscillation in the strength of cardiac muscle contraction at a constant heart rate,
has been observed in patients with severe heart failure and in animal models of this condition.
Although MA is rare under resting conditions in individuals with controlled heart failure, at
higher heart rates it is more prevalent and likely to be sustained, as exemplified by pacing-
induced MA or dobutamine-induced MA. However, few studies have addressed the clinical
implications of dobutamine-induced MA in patients with heart failure. We therefore prospec‐
tively examined and compared the prognostic value of dobutamine- and pacing- induced MA
in ambulatory patients with idiopathic dilated myocardiopathy (IDCM) in sinus rhythm.[1]
Furthermore, this review addresses the clinical circumstances, relevance of MA, current
understanding with ideas about its mechanism, and some future perspectives.
2. Mechanical Alternans (MA)
2.1. History of MA
Phenomenon of alternating weak and strong beats observed in a heart which is contracting
with constant intervals between beats. It has a long history. Experimental descriptions first
appeared over a century ago, and since then there has been a sustained debate among clinicians
and physiologists about its origins and clinical significance. A clinical description of an
alternating pulse by Traube is often quoted as appearing earlier. [2] However, careful inspec‐
tion of his figure shows alternating interbeat intervals. In fact, Traube himself commented on
the alternation of intervals and used the term "bigeminus" in the title of his report, although
the true nature of this arrhythmia can only be guessed at since the electrocardiograms had yet
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to be invented at the time when Traube reported his case. MA has been studied in the intact
human and animal heart, in isolated muscle preparations, and most recently in isolated cardiac
muscle cells.
2.2. Induction of MA
The  ability  to  induce  MA  by  rapid  driving  frequencies  appears  to  be  a  fundamental
property  of  mammalian  ventricular  muscle.  Experimental  studies  have  shown  that  by
varying the pacing cycle length over a wide range, it is possible to define a critical cycle
length  (threshold)  for  the  induction  of  sustained  MA.[3]  Driving  the  heart  at  cycle
lengths shorter than the threshold cycle length may increase the amplitude of the beat-to-
beat oscillations in contraction strength.
3. Method
3.1. Pacing- and dobutamine- induced MA
It is more prevalent and likely to be sustained, as exemplified by pacing-induced MA. Right
atrial pacing was initiated at 80 beats per minute (bpm) and was increased in increments of 10
bpm. We selected steady-state LV pressure data for at least 2 min at the baseline and at each
pacing rate for analysis.[4] We calculated the maximum first derivative of LV pressure (LV
dP/dtmax) as an index of contractility. To evaluate LV isovolumic relaxation, we computed T1/2,
as previously described.[5] After the hemodynamic values had checked at baseline, dobuta‐
mine was infused intravenously at incremental doses of 5, 10, and 15 µg kg–1min–1 and
hemodynamic measurements were performed at the end of each 5-min infusion period. MA
was diagnosed if the pressure difference between the strong and weak beats was ≥4 mmHg
continuously in the analyzed LV pressure data, as previously described.[6]
We prospectively followed up all patients for the occurrence of primary events, which were
defined as cardiac death (from worsening heart failure or sudden death) or the unscheduled
readmission for decompensated heart failure. Noncardiac death was excluded.
4. Results
4.1. Classification of IDCM patients on the basis of dobutamine-induced MA
To identify on the basis of the classification by hemodynamic response to pacing or do‐
butamine  stress  testing,  patients  were  classified  into  three  groups:  those  who exhibited
neither  pacing-  nor  dobutamine-induced  MA (n  =  60,  group N),  those  who manifested
only pacing-induced MA (n = 20,  group P),  and those who developed both pacing- and
dobutamine-induced MA (n = 10, group D). All patients who did not develop pacing-in‐
duced MA also did not exhibit dobutamine-induced MA. LV pressure waveforms during
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atrial pacing at 120 bpm or after dobutamine infusion at 10 µg kg–1  min–1  are shown for
representative patients from each group (Fig. 1).
Figure 1. LV pressure waveforms during atrial pacing at 120 bpm and after infusion of dobutamine at a dose of 10 µg
kg–1 min–1 in representative patients of three study groups. The traces represent the lead II electrocardiogram (ECG),
LV pressure, and LV dP/dt. Both LV dP/dtmax and LV dP/dtmin showed alternating changes with LV pressure. Strong and
weak beats are indicated by s and w, respectively.
4.2. Baseline clinical data
There were no significant differences in age and sex among the three groups of patients (Table
1). All patients were classified as NYHA functional class I or II at the time of cardiac catheter‐
ization. The LV ejection fraction (EF) in groups P and D was significantly lower than that in
group N. There were also no significant differences in plasma brain natriuretic peptide (BNP)
or norepinephrine levels among the three groups.
The abundance of phospholamban mRNA was significantly lower in group D than in group
P. The SERCA2a/phospholamban mRNA ratio was significantly higher in group D than in
groups N and P (Table 2). The probability of event-free survival in group D was significantly




Figure 2. Kaplan-Meier analysis of the cumulative probability of event-free survival of the 90 IDCM study patients. Car‐
diac events were defined as hospitalization due to worsening heart failure and cardiac death. The probability of event-
free survival in group D was significantly lower than that in groups P and N by the log-rank test (P = 0.002).
Characteristic Group N (n = 60) Group P (n = 20) Group D (n = 10)
Age (years) 51 ± 12 50 ± 13 45 ± 11
Sex (M/F) 44 / 16 16 / 4 6 / 4
NYHA functional class I 32 (53%) 9 (45%) 5 (50%)
class II 28 (47%) 11 (55%) 5 (50%)
Medication
Diuretics 30 (50%) 17* (85%) 9* (90%)
ACE inhibitors or ARBs 42 (70%) 19 (95%) 7 (70%)
Beta blockers 22 (37%) 10 (50%) 5 (50%)
PAWP (mmHg) 10.7 ± 4.7 14.6 ± 6.2* 13.9 ± 7.2
Cardiac index (L min–1 m–2) 3.07 ± 0.55 2.83 ± 0.58 3.26 ± 0.66
LVEF (%) 38.9 ± 8.1 32.9 ± 9.6* 30.3 ± 9.0*
Plasma BNP (pg/mL) 100 ± 173 179 ± 186 249 ± 262
Plasma norepinephrine (pg/mL) 440 ± 221 689 ± 764 664 ± 324
*P < 0.05 versus group N. Abbreviations not defined in text: ACE, angiotensin-converting enzyme; ARB, angiotensin-II
receptor blocker; PAWP, pulmonary artery wedge pressure.
Table 1. Baseline clinical characteristics of patients in the three study groups.
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mRNA ratio Group N Group P Group D
SERCA2a/GAPDH 0.42 ± 0.15 0.41 ± 0.13 0.43 ± 0.13
Phospholamban/GAPDH 0.82 ± 0.45 1.01 ± 0.13 0.42 ± 0.24*
Ryanodine receptor 2/GAPDH 0.50 ± 0.19 0.53 ± 0.21 0.75 ± 0.17
SERCA2a/phospholamban 0.63 ± 0.31 0.59 ± 0.40 1.32 ± 0.95*†
SERCA2a/Na+-Ca2+ exchanger 0.57 ± 0.79 0.50 ± 0.56 0.27 ± 0.14
*P < 0.05 versus group P, †P < 0.05 versus group N.
Table 2. Quantitative RT-PCR analysis of the abundance of Ca2+-handling protein mRNAs in endomyocardial biopsy
specimens.
4.3. Univariate and multivariate analysis of cardiac events
Univariate  analysis  revealed that  dobutamine-induced MA,  pacing-induced MA,  NYHA
functional  class,  plasma BNP levels,  mitral  regurgitation,  pulmonary artery wedge pres‐
sure,  LV end-diastolic  volume index,  LV end-systolic  volume index,  LVEF,  LV end-dia‐
stolic  pressure  and  T½  were  significant  predictors  of  cardiac  events  (Table  3).  Then,
stepwise multivariate analysis  identified dobutamine-induced MA (odds ratio,  4.05;  95%
confidence interval,  1.35 to 12.2) as a significant independent predictor of cardiac events
(Table 4). Both T1/2 (odds ratio, 1.079; 95% confidence interval, 1.003 to 1.161) and plasma
BNP level (odds ratio, 1.002; 95% confidence interval, 1.0004 to 1.0038) were also signifi‐
cant independent predictors of cardiac events,  but with smaller odds ratios than that of
dobutamine-induced MA.
Univariate analysis
Parameter Event-free group Cardiac-event group
P
(n = 72) (n = 18 )
Dobutamine-induced MA
(group D/groups P and N) 4 / 68 6 / 12 0.0019
Pacing-induced MA
(groups D and P/group N) 20 / 52 10 / 8 0.04
Age (years) 50 ± 12 53 ± 14 0.34
Sex (M/F) 53 / 19 13 / 5 0.86
Body mass index (kg/m2) 24.4 ± 4.9 22.5 ± 2.6 0.15
NYHA functional class † 1.3 ± 0.5 1.6 ± 0.4 0.011
QRS duration (ms) 113 ± 27 112 ± 22 0.88
Beta blockers 55 (76%) 10 (56%) 0.58





Parameter Event-free group Cardiac-event group
P
(n = 72) (n = 18 )
Plasma BNP (pg/mL) 123 ± 238 228 ± 162 0.0013
eGFR (mL min–1 1.73 m–2) 74 ± 17 68 ± 18 0.089
Plasma norepinephrine (pg/mL) 521 ± 452 524 ± 292 0.32
E/E’ 15.6 ± 8.6 24.2 ± 8.4 0.227
PAWP (mmHg) 11.5 ± 5.3 13.7 ± 6.6 0.044
Cardiac index (L min–1 m–2) 3.02 ± 0.57 3.13 ± 0.64 0.85
LVEDVI (mL m–2) 73 ± 52 115 ± 79 0.02
LVESVI (mL m–2) 43 ± 36 84 ± 62 0.018
LVEF (%) 38.2 ± 8.7 32.8 ± 6.8 0.003
Heart rate (bpm) 76 ± 17 75 ± 14 0.34
LVEDP (mmHg) 12 ± 8 15 ± 9 0.019
LVSP (mmHg) 119 ± 19 116 ± 23 0.62
LV dP/dt max (mmHg/s) 1114 ± 263 1160 ± 263 0.73
T1/2 (ms) 39 ± 7 44 ± 4.7 0.0086
Table 3. Univariate of predictors of cardiac events.
Multivariate analysis
Parameter
β OR ( 95% CI ) P
Dobutamine-induced MA
(group D/groups P and N) 1.4 4.05 (1.35–12.2) 0.013
Plasma BNP (pg/mL) 0.0021 1.002 (1.0004–1.0038) 0.014
T1/2 (ms) 0.076 1.079 (1.0033–1.161) 0.041
Table 4. Multivariate analysis of predictors of cardiac events.
5. Impact of dobutamine-induced MA
5.1. Prognosis
The occurrence of dobutamine-induced MA was a clinical predictor of poor prognosis in
ambulatory patients with IDCM in sinus rhythm. Although there was no significant dif‐
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ference  in  LVEF  between  patients  who  manifested  only  pacing-induced  MA  and  those
who developed both pacing- and dobutamine-induced MA, the probability of event-free
survival in the latter group was significantly lower than that in the former. Multivariate
analysis  also revealed that  the occurrence of  dobutamine-induced MA was a  significant
independent predictor of cardiac events.
5.2. Mechanisms
Three general mechanisms have been proposed to account for the development of MA:
alteration of action potential duration, impaired ventricular relaxation, and abnormal intra‐
cellular Ca2+-handling.[7] The low relative ratio of phospholamban to SERCA reduces the
inhibition of SERCA and increases Ca2+-uptake; this enhances relaxation and contraction in the
human atrium. However, humans lacking phospholamban develop lethal IDCM.[8] SERCA2a
and ryanodine receptor 2 mRNA levels were similar in all three of our groups, whereas the
relative ratio of SERCA to phospholamban was significantly higher in patients with pacing-
and dobutamine-induced MA than in those with only pacing-induced MA or with no MA.
These results suggest that an imbalance between phospholamban and SERCA mRNA levels
in the abundant Ca2+-handling proteins is associated with dobutamine-induced MA. Kobaya‐
shi et al. reported that the amounts of mRNAs for the β1-adrenergic receptor and SERCA2a in
the myocardium were smaller in asymptomatic or mildly symptomatic IDCM patients with
reduced adrenergic myocardial contractile reserve than in those with preserved adrenergic
contractile reserves.[9] The occurrence of dobutamine-induced MA in our patients in the
present study might also reflect abnormal β1-adrenergic receptor signaling in the myocardium.
However, steady-state mRNA levels do not necessarily reflect the corresponding protein
levels, in particular because both mRNA and protein synthesis or degradation may be altered
in the failing heart.[10, 11] Further studies are needed to elucidate these issues.
In patients with heart failure, dobutamine-induced MA is highly prevalent[6] and mechanical
and visible T-wave alternans is detectable under tachycardia or catecholamine exposure.[4,
12] Dobutamine-induced MA may be attributed various factors, including an increase in the
heart rate as a result of dobutamine infusion, impaired LV contraction, the influence of preload,
and abnormal Ca2+ under pathophysiological conditions. Dobutamine is a β-stimulator that
increases both heart rate and LV contraction. The increase in heart rate, but not that in LV
contraction, is likely to be a trigger for the occurrence of dobutamine-induced MA. Therefore,
the increased occurrence of dopamine-induced MA in heart failure patients might be related
to their poor myocardial contractile reserve.
6. Conclusion
In conclusion, the occurrence of dobutamine-induced MA is a potentially useful clinical
predictor of poor prognosis in ambulatory patients with IDCM in sinus rhythm. Recent
guidelines for the management of heart failure emphasize the need for earlier identification of




tomatic LV systolic dysfunction.[13] The prevalence of cardiac events or cardiac death was
higher in patients with dobutamine- and pacing- induced MA than in those without it.
Assessment of dobutamine-induced MA in addition to routine clinical evaluation in patients
with IDCM may thus contribute to stratification of individuals into low- or high-risk groups.
The identification of pacing- or dobutamine-induced MA requires an invasive examination
and time-consuming hemodynamic stress assessment. The current trend in clinical medicine
is to find a non-invasive test with prognostic consequences. However, the hemodynamic
phenomenon by dobutamine stress testing might be also potentially useful marker for
predicting the occurrence of cardiac events.
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